期刊文献+

腹腔镜前列腺癌根治术对临床各期前列腺癌的影响 被引量:2

下载PDF
导出
摘要 目的评估腹腔镜前列腺根治术(LRP)治疗临床各期前列腺癌患者的安全性及有效性。方法选取在医院治疗的前列腺癌患者60例,根据前列腺癌TNM临床分期将患者分为3组:第1组为T_1期前列腺癌患者12例,第2组为T_2期前列腺癌患者24例,第3组为T3期前列腺癌患者14例。详细记录入选的所有符合标准的前列腺患者年龄、体质量指数(BMI)、前列腺特异性抗原(PSA)水平、术前组织切片评分(Gleason评分)和D'Amico分类;记录神经保留手术率、导尿时间、住院时间,随访5年生存率。结果第3组患者PSA水平和Gleason得分明显高/低于其他2组(P<0.01);第1组患者年龄和BMI均低于其他2组(P<0.01);根据D'Amico的风险分类,第3组患者风险最高(P<0.01)。所有患者术中切除淋巴结数为(13.9±6.3)。第1组患者神经保留手术率(单侧加双侧)明显高于其他2组患者(P<0.01)。3组患者导尿时间和住院时间比较差异均无统计学意义(P>0.05)。3组患者5年随访期间总生存率分别为50.0%(6/12)、54.2%(13/24)和50.0%(7/14),差异无统计学意义(P>0.05)。结论 LRP治疗临床各期前列腺癌是安全有效的,而且与T_1和T_2期前列腺癌患者在随访期具有相似的总生存率。
出处 《临床合理用药杂志》 2018年第22期141-142,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献7

二级参考文献147

  • 1张旭,王少刚,叶章群,李宏召,郑涛,马鑫,黄本荣.腹腔镜前列腺癌根治术治疗早期前列腺癌的临床经验(附10例报告)[J].临床泌尿外科杂志,2004,19(9):516-518. 被引量:35
  • 2Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [ J ]. CA Cancer J Clin,2012,62 ( 1 ) : 10-29.
  • 3Tannock I, Osoba D, Stockler M R, et al. Chemothera- py with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Ca- nadian randomized trial with palliative end points [ J ]. J Clin Oncol, 1996,14(6) : 1756-1764.
  • 4Kantoff P W, Halabi S, Conaway M, et al. Hydrocorti- sone with or without mitoxantrone in men with hormone refractory prostate cancer: results of the cancer and leu- kemia group B 9182 study [ J ]. J Clin Oncol, 1999,17 (8) :2506-2513.
  • 5Holzbeierlein J, Lal P, Latulippe E, et al. Gene expres- sion analysis of human prostate eareinoma during hormo- nal therapy identifies androgen-responsive genes and mechanisms of therapy resistance [ J ]. Am J Pathol, 2004,164( 1 ) :217-227.
  • 6Locke J A, Guns E S, Lubik A A, et al. Androgen lev- els increase by intratumoral de novo steroidogenesis dur- ing progression of castration-resistant prostate cancer [ J]. Cancer Res, 2008,68 ( 15 ) :6407-6415.
  • 7Mostaghel E A, Page S T, Lin D W, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer [ J ]. Cancer Res, 2007,67(10) :5033-5041.
  • 8Attard G, Reid A, Auchus R, et al. Clinical and bio- chemical consequences of CYP17A1 inhibition with abi- raterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer[J]. J Clin Endocrinol Metab, 2012,97 ( 2 ) :507-516.
  • 9Handratta V D, Vasaitis T S, Njar V C, et al. Novel C- 17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model[J]. J Med Chem, 2005,48 ( 8 ) : 2972-2984.
  • 10Attard G, Belldegrun A S, de Bono J S. Selective block- ade of androgenic steroid synthesis by novel lyase inhibi- tors as a therapeutic strategy for treating metastatic pros- tate cancer[ J ]. BJU Int, 2005,96 ( 9 ) : 1241-1246.

共引文献78

同被引文献11

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部